CIMERLI

CIMERLI™ is contraindicated in patients with ocular or periocular infections or known hypersensitivity to ranibizumab products or any of the excipients in CIMERLI™. Hypersensitivity reactions may manifest as severe intraocular inflammation... CIMERLI™ is the first and only FDA-approved interchangeable ranibizumab biosimilar with attributes identical to Lucentis®